| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | ERBB4; HER4; Receptor tyrosine-protein kinase erbB-4; Proto-oncogene-like protein c-ErbB-4; Tyrosine kinase-type cell surface receptor HER4; p180erbB4 |
| Entrez GeneID | 2066 |
| WB Predicted band size | Calculated MW: 147 kDa; Observed MW: 180 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Rat |
| Immunogen | Recombinant protein of human ErbB 4 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于ErbB4抗体的3篇代表性文献的模拟示例(注：以下内容为假设性描述，实际文献需通过数据库检索确认)：
---
1. **文献名称**: "Anti-ErbB4 monoclonal antibody inhibits ligand-induced receptor activation in breast cancer models"
**作者**: Jones, R.B., et al.
**摘要**: 该研究开发了一种靶向ErbB4胞外域的单克隆抗体，证实其能特异性阻断神经调节蛋白(neuregulin)介导的ErbB4受体二聚化及下游PI3K/AKT信号通路，显著抑制乳腺癌细胞的增殖和迁移。
---
2. **文献名称**: "ErbB4 antibody-based therapy suppresses tumor growth in glioblastoma xenografts"
**作者**: Huang, L., & Egeblad, M.
**摘要**: 通过构建靶向ErbB4的抗体-药物偶联物(ADC)，研究证明其在胶质母细胞瘤异种移植模型中可诱导肿瘤细胞凋亡，并抑制血管生成，提示ErbB4抗体在实体瘤治疗中的潜在应用价值。
---
3. **文献名称**: "Differential effects of ErbB4 antibodies on receptor endocytosis and synaptic plasticity"
**作者**: Zhou, W., et al.
**摘要**: 比较两种ErbB4抗体对神经元受体内吞和突触功能的影响，发现特定表位抗体可调控ErbB4的膜稳定性，进而影响海马神经元的长期增强(LTP)过程，为神经精神疾病治疗提供新思路。
---
如需真实文献，建议通过PubMed或Google Scholar检索关键词(如"ErbB4 antibody therapeutic"、"HER4 inhibitor"等)，并筛选近5年高被引论文。
ErbB4. also known as HER4. is a member of the epidermal growth factor receptor (EGFR) tyrosine kinase family. It plays critical roles in cell proliferation, differentiation, and survival by binding ligands like neuregulins. Upon activation, ErbB4 forms homodimers or heterodimers with other EGFR members (e.g., ErbB2), triggering downstream signaling pathways such as MAPK and PI3K-Akt. Dysregulation of ErbB4 is implicated in cancers, cardiovascular diseases, and neurological disorders, though its role varies contextually (e.g., acting as an oncogene or tumor suppressor).
ErbB4 antibodies are essential tools for studying its expression, activation, and signaling mechanisms. Monoclonal and polyclonal antibodies target specific extracellular or intracellular domains, enabling applications in immunohistochemistry, Western blotting, and flow cytometry. Therapeutic antibodies against ErbB4 are under exploration to modulate its activity in diseases. For instance, blocking antibodies may inhibit oncogenic signaling in certain cancers, while others aim to restore protective functions in heart failure.
Challenges include ErbB4’s complex post-translational processing (e.g., proteolytic cleavage producing soluble intracellular domains) and isoform diversity, which influence antibody specificity. Research continues to clarify its dual roles and optimize antibody-based strategies for diagnostics and targeted therapies.
×
